var data={"title":"Management of antiplatelet agents in patients undergoing endoscopic procedures","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Management of antiplatelet agents in patients undergoing endoscopic procedures</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/contributors\" class=\"contributor contributor_credentials\">Patrick S Kamath, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/contributors\" class=\"contributor contributor_credentials\">John R Saltzman, MD, FACP, FACG, FASGE, AGAF</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/contributors\" class=\"contributor contributor_credentials\">Kristen M Robson, MD, MBA, FACG</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 26, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Gastroenterologic procedures are commonly performed in patients taking antiplatelet agents. However, there are limited data assessing the bleeding risk of specific procedures in these settings.</p><p>This topic will review the periprocedural management of patients taking antiplatelet agents. The management of patients taking anticoagulants, as well as patients with von Willebrand's disease, hemophilia, renal failure, liver failure, and thrombocytopenia are discussed elsewhere. (See <a href=\"topic.htm?path=management-of-anticoagulants-in-patients-undergoing-endoscopic-procedures\" class=\"medical medical_review\">&quot;Management of anticoagulants in patients undergoing endoscopic procedures&quot;</a> and <a href=\"topic.htm?path=endoscopic-procedures-in-patients-with-disorders-of-hemostasis\" class=\"medical medical_review\">&quot;Endoscopic procedures in patients with disorders of hemostasis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">SOCIETY GUIDELINES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The American Society for Gastrointestinal Endoscopy (ASGE) has issued <a href=\"http://ac.els-cdn.com/S0016510715029508/1-s2.0-S0016510715029508-main.pdf?_tid=a0693c82-ba09-11e5-8978-00000aab0f01&acdnat=1452698801_9df67ae11363efbf2b6fa3632bbd80fc&amp;token=cNg55jeMxmwL45iSEtS/ojU2gWp+WUfpiLJHO37EokoWGXm2ba1yVfcCQPW5qZUJ0wumB5+4dY6/ayEHfa/N+2aEQmdsRRzLp93e4M5Qe3T5ZeSwuQ0uto7BIXwH3M4ekEZ/LxlM63WXAb9SrxUTnH0b/EW+qclyzA9OtMrL3TtKBEoBk9ESha+LwbHS5CFj&amp;TOPIC_ID=2632\" target=\"_blank\" class=\"external\">official guidelines</a> based upon the available evidence and consensus opinion [<a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/1\" class=\"abstract_t\">1</a>]. The recommendations in this topic review are consistent with the ASGE guidelines. This topic is also addressed in reviews and guidelines from the American College of Gastroenterology, the American College of Chest Physicians, the American College of Cardiology, and the British Society of <span class=\"nowrap\">Gastroenterology/European</span> Society of Gastrointestinal Endoscopy, which make similar (though not identical) recommendations [<a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/2-5\" class=\"abstract_t\">2-5</a>]. The management of newer antiplatelet agents (such as <a href=\"topic.htm?path=prasugrel-drug-information\" class=\"drug drug_general\">prasugrel</a> or <a href=\"topic.htm?path=ticagrelor-drug-information\" class=\"drug drug_general\">ticagrelor</a>) has been the subject of review articles [<a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/6,7\" class=\"abstract_t\">6,7</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">PROCEDURE-RELATED BLEEDING RISK</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In general, diagnostic endoscopic procedures are at much lower risk for bleeding than are therapeutic procedures (<a href=\"image.htm?imageKey=GAST%2F50700\" class=\"graphic graphic_table graphicRef50700 \">table 1</a>). High-risk procedures are those with a bleeding risk of greater than 1.5 percent. The procedure-related bleeding risk of various endoscopic procedures is discussed in detail elsewhere. (See <a href=\"topic.htm?path=endoscopic-procedures-in-patients-with-disorders-of-hemostasis#H3\" class=\"medical medical_review\">&quot;Endoscopic procedures in patients with disorders of hemostasis&quot;, section on 'Procedure-related bleeding risk'</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">RISK OF THROMBOEMBOLIC COMPLICATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The probability of a thromboembolic complication following reversal or discontinuation of anticoagulation or antiplatelet agents depends upon the preexisting condition for which the medication was prescribed (<a href=\"image.htm?imageKey=GAST%2F77634\" class=\"graphic graphic_table graphicRef77634 \">table 2</a>). This topic is discussed in detail elsewhere. (See <a href=\"topic.htm?path=perioperative-management-of-patients-receiving-anticoagulants#H3\" class=\"medical medical_review\">&quot;Perioperative management of patients receiving anticoagulants&quot;, section on 'Estimating thromboembolic risk'</a> and <a href=\"topic.htm?path=noncardiac-surgery-after-percutaneous-coronary-intervention#H350963235\" class=\"medical medical_review\">&quot;Noncardiac surgery after percutaneous coronary intervention&quot;, section on 'Complications'</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">ELECTIVE PROCEDURES IN PATIENTS ON ANTIPLATELET AGENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antiplatelet agents can be classified based on their mechanisms of action (<a href=\"image.htm?imageKey=CARD%2F75709\" class=\"graphic graphic_figure graphicRef75709 \">figure 1</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">Aspirin</a> (acetylsalicylic acid) and related compounds (nonsteroidal anti-inflammatory drugs and sulfinpyrazone) block cyclooxygenase, the enzyme that mediates the first step in prostaglandin and thromboxane biosynthesis from arachidonic acid.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=dipyridamole-drug-information\" class=\"drug drug_general\">Dipyridamole</a> inhibits phosphodiesterase-mediated breakdown of cyclic AMP, which prevents platelet activation by multiple mechanisms.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>P2Y<sub>12</sub> platelet receptor blockers (eg, <a href=\"topic.htm?path=ticlopidine-united-states-not-available-drug-information\" class=\"drug drug_general\">ticlopidine</a>, <a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">clopidogrel</a>, <a href=\"topic.htm?path=prasugrel-drug-information\" class=\"drug drug_general\">prasugrel</a>, <a href=\"topic.htm?path=ticagrelor-drug-information\" class=\"drug drug_general\">ticagrelor</a>) achieve their antiplatelet effect by blocking the binding of ADP to a specific platelet receptor (P2Y<sub>12</sub>), inhibiting adenylyl cyclase and platelet aggregation [<a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/8\" class=\"abstract_t\">8</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Glycoprotein <span class=\"nowrap\">IIb/IIIa</span> antibodies and receptor antagonists (eg, <a href=\"topic.htm?path=abciximab-drug-information\" class=\"drug drug_general\">abciximab</a>, roxifiban, <a href=\"topic.htm?path=eptifibatide-drug-information\" class=\"drug drug_general\">eptifibatide</a>, <a href=\"topic.htm?path=tirofiban-drug-information\" class=\"drug drug_general\">tirofiban</a>, orbofiban, sibrafiban) inhibit the final common pathway of platelet aggregation and may also prevent initial adhesion to the vessel wall.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Competitive and selective inhibitors of PAR-1 (the major thrombin receptor on platelets; eg, <a href=\"topic.htm?path=vorapaxar-drug-information\" class=\"drug drug_general\">vorapaxar</a>).</p><p/><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Aspirin and NSAIDs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">Aspirin</a> and other nonsteroidal antiinflammatory drugs (NSAIDs) given alone in standard doses do not appear to increase the risk of significant bleeding after upper endoscopy with biopsy, colonoscopy with biopsy, or biliary sphincterotomy [<a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/9-13\" class=\"abstract_t\">9-13</a>]. However, data are conflicting regarding whether there is an increased risk of postpolypectomy bleeding in patients taking aspirin <span class=\"nowrap\">and/or</span> NSAIDs. In a preliminary report of a retrospective study of 3191 colonoscopies with polypectomy, patients who received both aspirin and another NSAID had an increased risk of immediate post-polypectomy bleeding compared with those who did not (odds ratio 14) [<a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/14\" class=\"abstract_t\">14</a>]. However, a subsequent study of 1174 patients who underwent polypectomy found no difference in postpolypectomy bleeding rates among those who received aspirin <span class=\"nowrap\">and/or</span> an NSAID and those who did not (3.2 versus 3.0 percent) [<a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/15\" class=\"abstract_t\">15</a>]. While it is unclear if aspirin <span class=\"nowrap\">and/or</span> NSAID increase postpolypectomy bleeding, the combination of aspirin or other NSAIDS with <a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">clopidogrel</a> may increase the risk of postpolypectomy bleeding. (See <a href=\"#H8\" class=\"local\">'P2Y12 platelet receptor blockers'</a> below.)</p><p><a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">Aspirin</a> and NSAIDS do <strong>not</strong> need to be discontinued for endoscopic procedures. However, for patients undergoing high-risk procedures (<a href=\"image.htm?imageKey=GAST%2F50700\" class=\"graphic graphic_table graphicRef50700 \">table 1</a>), some clinicians elect to stop aspirin and NSAIDs five to seven days prior to the procedure, taking into account the underlying indication for the antiplatelet therapy. In addition, if patients are on aspirin combined with another NSAID, it may be prudent to hold the NSAID if possible.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Dipyridamole</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the absence of a preexisting bleeding disorder, endoscopic procedures may be performed in patients who take <a href=\"topic.htm?path=dipyridamole-drug-information\" class=\"drug drug_general\">dipyridamole</a> or combination dipyridamole-aspirin in standard doses (<a href=\"image.htm?imageKey=GAST%2F64448\" class=\"graphic graphic_table graphicRef64448 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/16\" class=\"abstract_t\">16</a>]. However, the safety in patients undergoing high-risk procedures is unknown.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">P2Y12 platelet receptor blockers</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The P2Y<sub>12</sub> platelet receptor blockers include <a href=\"topic.htm?path=ticlopidine-united-states-not-available-drug-information\" class=\"drug drug_general\">ticlopidine</a>, <a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">clopidogrel</a>, <a href=\"topic.htm?path=prasugrel-drug-information\" class=\"drug drug_general\">prasugrel</a>, and <a href=\"topic.htm?path=ticagrelor-drug-information\" class=\"drug drug_general\">ticagrelor</a>. The decision to discontinue a P2Y<sub>12</sub> platelet receptor blocker before endoscopy should take into account the potential risk of stopping the medication, and consultation with the patient's cardiologist or neurologist should be considered before stopping these agents.</p><p>These drugs are frequently used in combination with other antiplatelet agents. Dual antiplatelet therapy (DAPT) with <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> and a P2Y<sub>12</sub> platelet receptor blocker is used in the treatment of patients with vascular stents, acute coronary syndromes, and cerebrovascular disease.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=long-term-antiplatelet-therapy-after-coronary-artery-stenting-in-stable-patients\" class=\"medical medical_review\">&quot;Long-term antiplatelet therapy after coronary artery stenting in stable patients&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=antiplatelet-agents-in-acute-st-elevation-myocardial-infarction\" class=\"medical medical_review\">&quot;Antiplatelet agents in acute ST elevation myocardial infarction&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=antiplatelet-agents-in-acute-non-st-elevation-acute-coronary-syndromes\" class=\"medical medical_review\">&quot;Antiplatelet agents in acute non-ST elevation acute coronary syndromes&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=antiplatelet-therapy-for-secondary-prevention-of-stroke\" class=\"medical medical_review\">&quot;Antiplatelet therapy for secondary prevention of stroke&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=antithrombotic-therapy-for-elective-percutaneous-coronary-intervention-general-use\" class=\"medical medical_review\">&quot;Antithrombotic therapy for elective percutaneous coronary intervention: General use&quot;</a>.)</p><p/><p>Some studies suggest that the use of P2Y<sub>12</sub> platelet receptor blockers or DAPT may increase the risk of upper gastrointestinal bleeding and post-polypectomy bleeding [<a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/3,14,17,18\" class=\"abstract_t\">3,14,17,18</a>]. The effect of <a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">clopidogrel</a> on post-polypectomy bleeding was examined in a meta-analysis of five observational studies with 6743 patients [<a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/19\" class=\"abstract_t\">19</a>]. At the time of colonoscopy, 574 patients (8.5 percent) were taking clopidogrel, with or without <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>. Post-polypectomy bleeding developed in 6.5 percent of patients who were receiving clopidogrel, compared with 1.7 percent of patients who were not (relative risk [RR] 2.5, 95% CI 1.7-3.8). Clopidogrel use did not appear to increase the risk of immediate post-polypectomy bleeding (RR 1.8; 95% CI 0.9-3.5), but it did increase the risk of delayed bleeding (RR 4.7, 95% CI 2.4-14).</p><p>P2Y<sub>12</sub> platelet receptor blockers do <strong>not</strong> need to be discontinued for low-risk procedures (<a href=\"image.htm?imageKey=GAST%2F50700\" class=\"graphic graphic_table graphicRef50700 \">table 1</a> and <a href=\"image.htm?imageKey=GAST%2F64448\" class=\"graphic graphic_table graphicRef64448 \">table 3</a>). For high-risk procedures in patients with low thromboembolic risk (<a href=\"image.htm?imageKey=GAST%2F77634\" class=\"graphic graphic_table graphicRef77634 \">table 2</a>), the recommended duration for discontinuing the agent prior to the procedure is as follows: five days (<a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">clopidogrel</a>), three to five days (<a href=\"topic.htm?path=ticagrelor-drug-information\" class=\"drug drug_general\">ticagrelor</a>), seven days (<a href=\"topic.htm?path=prasugrel-drug-information\" class=\"drug drug_general\">prasugrel</a>), or 10 to 14 days (<a href=\"topic.htm?path=ticlopidine-united-states-not-available-drug-information\" class=\"drug drug_general\">ticlopidine</a>) [<a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/6,7,20\" class=\"abstract_t\">6,7,20</a>].</p><p>Discontinuing P2Y<sub>12</sub> platelet receptor blockers should also be considered in patients at high risk for thromboembolic complications who are undergoing high-risk procedures, if the risk of bleeding is thought to outweigh the risk of thromboembolism. <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">Aspirin</a> need not be discontinued. For patients not on aspirin, the addition of aspirin during the periendoscopic period may decrease the risk of thromboembolic events [<a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/1\" class=\"abstract_t\">1</a>], though this does not appear to be the case in patients undergoing noncardiac surgical procedures [<a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/21\" class=\"abstract_t\">21</a>].</p><p>For patients with cardiac stents, the American Society of Gastrointestinal Endoscopy (ASGE) guidelines recommend avoiding elective procedures until the patient has received antithrombotic therapy for the minimum recommended duration based upon current guidelines [<a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/1\" class=\"abstract_t\">1</a>]. Once beyond that period, depending on the agent used, P2Y<sub>12</sub> platelet receptor blockers are discontinued 5 to 14 days prior to the procedure, while continuing <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>. This issue is also discussed in guidelines from the American College of Chest Physicians for patients undergoing surgical procedures [<a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/4\" class=\"abstract_t\">4</a>]. The guidelines recommend that patients who are within six weeks of bare-metal stent placement or within six months of drug-eluting stent placement have surgical procedures deferred, when possible, until after six weeks and six months of placement, respectively. (See <a href=\"topic.htm?path=long-term-antiplatelet-therapy-after-coronary-artery-stenting-in-stable-patients\" class=\"medical medical_review\">&quot;Long-term antiplatelet therapy after coronary artery stenting in stable patients&quot;</a>.)</p><p>Following the procedure, the P2Y<sub>12</sub> platelet receptor blocker should be restarted, with or without a loading dose, as soon as it is deemed safe, taking into account the patient's indication for taking it and any therapy performed during the endoscopy that may increase the risk for bleeding (such as removal of a large polyp) [<a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H2678679555\"><span class=\"h2\">Other agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients undergoing elective procedures are typically not taking <span class=\"nowrap\">GPIIb/IIIa</span> inhibitors. For patients taking the PAR-1 inhibitor <a href=\"topic.htm?path=vorapaxar-drug-information\" class=\"drug drug_general\">vorapaxar</a>, the drug should be held for 5 to 13 days prior to elective endoscopy (<a href=\"image.htm?imageKey=GAST%2F64448\" class=\"graphic graphic_table graphicRef64448 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">URGENT PROCEDURES IN PATIENTS ON ANTIPLATELET AGENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are limited data regarding the management of patients on antiplatelet agents for acute coronary syndromes or a recently placed vascular stent who need urgent endoscopy (<a href=\"image.htm?imageKey=GAST%2F64448\" class=\"graphic graphic_table graphicRef64448 \">table 3</a>). A cardiology consultation should be obtained to assist with management of the antiplatelet agents. The American Society of Gastrointestinal Endoscopy (ASGE) guidelines suggest holding antiplatelet agents for patients with life-threatening or serious bleeding after discussion with the patient's cardiologist [<a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/1\" class=\"abstract_t\">1</a>]. We typically resume antiplatelet agents in these patients once hemostasis has been achieved. However, consideration should be given to continuing dual antiplatelet therapy in patients who have had a bare-metal stent placed within the preceding six weeks or drug-eluting stents within the preceding six months. Once hemostasis has been achieved, the antiplatelet agent(s) should be restarted. A double dose of <a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">clopidogrel</a> can be used in patients with coronary stents if the risk of bleeding is lower than originally anticipated (eg, if a large colonic polyp is biopsied rather than removed).</p><p>We recommend caution when resuming rapidly acting agents such as <a href=\"topic.htm?path=prasugrel-drug-information\" class=\"drug drug_general\">prasugrel</a> or <a href=\"topic.htm?path=ticagrelor-drug-information\" class=\"drug drug_general\">ticagrelor</a>, especially since there are no agents that can reverse their action. In cases of life-threatening or serious bleeding, platelet transfusion may be required, though efficacy may be limited. </p><p>For patients on <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> or nonsteroidal anti-inflammatory drugs (NSAIDS) for other reasons (eg, for primary prevention or for the treatment of pain), the antiplatelet agent should be discontinued. Aspirin and NSAIDS can be reinitiated within 24 hours after the procedure.</p><p><span class=\"nowrap\">GPIIb/IIIa</span> inhibitors and the PAR-1 inhibitor <a href=\"topic.htm?path=vorapaxar-drug-information\" class=\"drug drug_general\">vorapaxar</a> should be stopped in patients who require emergency endoscopy. The duration of action of these agents ranges from seconds (<a href=\"topic.htm?path=tirofiban-drug-information\" class=\"drug drug_general\">tirofiban</a>), to hours (<a href=\"topic.htm?path=abciximab-drug-information\" class=\"drug drug_general\">abciximab</a>), to days (vorapaxar) (<a href=\"image.htm?imageKey=GAST%2F64448\" class=\"graphic graphic_table graphicRef64448 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/1\" class=\"abstract_t\">1</a>].</p><p>We continue proton pump inhibitor therapy as long as patients are on antiplatelet agents, especially in patients at higher risk for gastroduodenal toxicity. In patients with peptic ulcers and <em>Helicobacter pylori</em> infection, we also initiate therapy to eradicate the <em>H. pylori</em>. (See <a href=\"topic.htm?path=nsaids-including-aspirin-secondary-prevention-of-gastroduodenal-toxicity#H2\" class=\"medical medical_review\">&quot;NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity&quot;, section on 'Secondary prevention of gastroduodenal toxicity'</a> and <a href=\"topic.htm?path=treatment-regimens-for-helicobacter-pylori\" class=\"medical medical_review\">&quot;Treatment regimens for Helicobacter pylori&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The risk of bleeding from endoscopic procedures can be classified as high or low. In general, diagnostic procedures are low risk, whereas therapeutic procedures are high risk (<a href=\"image.htm?imageKey=GAST%2F50700\" class=\"graphic graphic_table graphicRef50700 \">table 1</a>). (See <a href=\"topic.htm?path=endoscopic-procedures-in-patients-with-disorders-of-hemostasis#H3\" class=\"medical medical_review\">&quot;Endoscopic procedures in patients with disorders of hemostasis&quot;, section on 'Procedure-related bleeding risk'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The probability of a thromboembolic complication following reversal or discontinuation of anticoagulation or antiplatelet agents depends upon the preexisting condition for which the medication was prescribed (<a href=\"image.htm?imageKey=GAST%2F77634\" class=\"graphic graphic_table graphicRef77634 \">table 2</a>). (See <a href=\"topic.htm?path=perioperative-management-of-patients-receiving-anticoagulants#H3\" class=\"medical medical_review\">&quot;Perioperative management of patients receiving anticoagulants&quot;, section on 'Estimating thromboembolic risk'</a> and <a href=\"topic.htm?path=noncardiac-surgery-after-percutaneous-coronary-intervention#H350963235\" class=\"medical medical_review\">&quot;Noncardiac surgery after percutaneous coronary intervention&quot;, section on 'Complications'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest that <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> and other nonsteroidal antiinflammatory drugs (NSAIDs) given alone and in standard doses be continued for elective endoscopic procedures (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H6\" class=\"local\">'Aspirin and NSAIDs'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The decision regarding whether a P2Y<sub>12</sub> platelet receptor blocker (eg, <a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">clopidogrel</a>) should be discontinued before endoscopy should be weighed against the potential risk of a thromboembolic complication. We suggest consultation with a cardiologist or neurologist (depending on the indication for the medication) prior to discontinuing it. (See <a href=\"#H8\" class=\"local\">'P2Y12 platelet receptor blockers'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The duration of holding a P2Y<sub>12</sub> platelet receptor blocker prior to a high-risk procedure is as follows: five days (<a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">clopidogrel</a>), three to five days (<a href=\"topic.htm?path=ticagrelor-drug-information\" class=\"drug drug_general\">ticagrelor</a>), seven days (<a href=\"topic.htm?path=prasugrel-drug-information\" class=\"drug drug_general\">prasugrel</a>), or 10 to 14 days (<a href=\"topic.htm?path=ticlopidine-united-states-not-available-drug-information\" class=\"drug drug_general\">ticlopidine</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients on dual antiplatelet therapy with a P2Y<sub>12</sub> platelet receptor blocker and <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> undergoing high-risk procedures, if the P2Y<sub>12</sub> platelet receptor blocker is going to be held, we suggest continuing the patient on aspirin (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H8\" class=\"local\">'P2Y12 platelet receptor blockers'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Following the procedure, the P2Y<sub>12</sub> platelet receptor blocker should be restarted as soon as it is deemed safe, taking into account the patient's indication for taking it and any therapy performed during the endoscopy that may increase the risk for bleeding. (See <a href=\"#H8\" class=\"local\">'P2Y12 platelet receptor blockers'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The management of patients taking anticoagulants is discussed in detail elsewhere. (See <a href=\"topic.htm?path=management-of-anticoagulants-in-patients-undergoing-endoscopic-procedures\" class=\"medical medical_review\">&quot;Management of anticoagulants in patients undergoing endoscopic procedures&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other disorders of hemostasis that may require treatment prior to gastrointestinal procedures, including von Willebrand's disease, hemophilia A and B, renal failure, liver failure, and thrombocytopenia, are discussed in detail elsewhere. (See <a href=\"topic.htm?path=endoscopic-procedures-in-patients-with-disorders-of-hemostasis\" class=\"medical medical_review\">&quot;Endoscopic procedures in patients with disorders of hemostasis&quot;</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/1\" class=\"nounderline abstract_t\">ASGE Standards of Practice Committee, Acosta RD, Abraham NS, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc 2016; 83:3.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/2\" class=\"nounderline abstract_t\">Kwok A, Faigel DO. Management of anticoagulation before and after gastrointestinal endoscopy. Am J Gastroenterol 2009; 104:3085.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/3\" class=\"nounderline abstract_t\">Becker RC, Scheiman J, Dauerman HL, et al. Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. J Am Coll Cardiol 2009; 54:2261.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/4\" class=\"nounderline abstract_t\">Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e326S.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/5\" class=\"nounderline abstract_t\">Veitch AM, Vanbiervliet G, Gershlick AH, et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Gut 2016; 65:374.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/6\" class=\"nounderline abstract_t\">Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 2013; 368:2113.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/7\" class=\"nounderline abstract_t\">Baron TH, Kamath PS, McBane RD. New anticoagulant and antiplatelet agents: a primer for the gastroenterologist. Clin Gastroenterol Hepatol 2014; 12:187.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/8\" class=\"nounderline abstract_t\">Foster CJ, Prosser DM, Agans JM, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001; 107:1591.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/9\" class=\"nounderline abstract_t\">Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37:383.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/10\" class=\"nounderline abstract_t\">Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/11\" class=\"nounderline abstract_t\">Shiffman ML, Farrel MT, Yee YS. Risk of bleeding after endoscopic biopsy or polypectomy in patients taking aspirin or other NSAIDS. Gastrointest Endosc 1994; 40:458.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/12\" class=\"nounderline abstract_t\">Hussain N, Alsulaiman R, Burtin P, et al. The safety of endoscopic sphincterotomy in patients receiving antiplatelet agents: a case-control study. Aliment Pharmacol Ther 2007; 25:579.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/13\" class=\"nounderline abstract_t\">Hamada T, Yasunaga H, Nakai Y, et al. Bleeding after endoscopic sphincterotomy or papillary balloon dilation among users of antithrombotic agents. Endoscopy 2015; 47:997.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/14\" class=\"nounderline abstract_t\">Grossman EB, Maranino AN, Zamora DC, et al. Antiplatelet medications increase the risk of post-polypectomy bleeding. Gastrointest Endosc 2010; 71:AB138.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/15\" class=\"nounderline abstract_t\">Manocha D, Singh M, Mehta N, Murthy UK. Bleeding risk after invasive procedures in aspirin/NSAID users: polypectomy study in veterans. Am J Med 2012; 125:1222.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/16\" class=\"nounderline abstract_t\">Zuckerman MJ, Hirota WK, Adler DG, et al. ASGE guideline: the management of low-molecular-weight heparin and nonaspirin antiplatelet agents for endoscopic procedures. Gastrointest Endosc 2005; 61:189.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/17\" class=\"nounderline abstract_t\">Singh M, Mehta N, Murthy UK, et al. Postpolypectomy bleeding in patients undergoing colonoscopy on uninterrupted clopidogrel therapy. Gastrointest Endosc 2010; 71:998.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/18\" class=\"nounderline abstract_t\">Feagins LA, Iqbal R, Harford WV, et al. Low rate of postpolypectomy bleeding among patients who continue thienopyridine therapy during colonoscopy. Clin Gastroenterol Hepatol 2013; 11:1325.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/19\" class=\"nounderline abstract_t\">Gandhi S, Narula N, Mosleh W, et al. Meta-analysis: colonoscopic post-polypectomy bleeding in patients on continued clopidogrel therapy. Aliment Pharmacol Ther 2013; 37:947.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/20\" class=\"nounderline abstract_t\">Bousti&egrave;re C, Veitch A, Vanbiervliet G, et al. Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2011; 43:445.</a></li><li><a href=\"https://www.uptodate.com/contents/management-of-antiplatelet-agents-in-patients-undergoing-endoscopic-procedures/abstract/21\" class=\"nounderline abstract_t\">Devereaux PJ, Mrkobrada M, Sessler DI, et al. Aspirin in patients undergoing noncardiac surgery. N Engl J Med 2014; 370:1494.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2632 Version 21.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H10\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">SOCIETY GUIDELINES</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">PROCEDURE-RELATED BLEEDING RISK</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">RISK OF THROMBOEMBOLIC COMPLICATIONS</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">ELECTIVE PROCEDURES IN PATIENTS ON ANTIPLATELET AGENTS</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">Aspirin and NSAIDs</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Dipyridamole</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">P2Y12 platelet receptor blockers</a></li><li><a href=\"#H2678679555\" id=\"outline-link-H2678679555\">Other agents</a></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">URGENT PROCEDURES IN PATIENTS ON ANTIPLATELET AGENTS</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"GAST/2632|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/75709\" class=\"graphic graphic_figure\">- Mechanism antiplatelet agents</a></li></ul></li><li><div id=\"GAST/2632|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/50700\" class=\"graphic graphic_table\">- Bleeding risk GI procedure</a></li><li><a href=\"image.htm?imageKey=GAST/77634\" class=\"graphic graphic_table\">- Risk GI procedure conditions</a></li><li><a href=\"image.htm?imageKey=GAST/64448\" class=\"graphic graphic_table\">- Newer antiplatelet ASGE</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=antiplatelet-agents-in-acute-st-elevation-myocardial-infarction\" class=\"medical medical_review\">Antiplatelet agents in acute ST elevation myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antiplatelet-agents-in-acute-non-st-elevation-acute-coronary-syndromes\" class=\"medical medical_review\">Antiplatelet agents in acute non-ST elevation acute coronary syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antiplatelet-therapy-for-secondary-prevention-of-stroke\" class=\"medical medical_review\">Antiplatelet therapy for secondary prevention of stroke</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antithrombotic-therapy-for-elective-percutaneous-coronary-intervention-general-use\" class=\"medical medical_review\">Antithrombotic therapy for elective percutaneous coronary intervention: General use</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=endoscopic-procedures-in-patients-with-disorders-of-hemostasis\" class=\"medical medical_review\">Endoscopic procedures in patients with disorders of hemostasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=long-term-antiplatelet-therapy-after-coronary-artery-stenting-in-stable-patients\" class=\"medical medical_review\">Long-term antiplatelet therapy after coronary artery stenting in stable patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-anticoagulants-in-patients-undergoing-endoscopic-procedures\" class=\"medical medical_review\">Management of anticoagulants in patients undergoing endoscopic procedures</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nsaids-including-aspirin-secondary-prevention-of-gastroduodenal-toxicity\" class=\"medical medical_review\">NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=noncardiac-surgery-after-percutaneous-coronary-intervention\" class=\"medical medical_review\">Noncardiac surgery after percutaneous coronary intervention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=perioperative-management-of-patients-receiving-anticoagulants\" class=\"medical medical_review\">Perioperative management of patients receiving anticoagulants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-regimens-for-helicobacter-pylori\" class=\"medical medical_review\">Treatment regimens for Helicobacter pylori</a></li></ul></div></div>","javascript":null}